References
- Balliet RM, Chen G, Gallagher CJ, et al. (2009). Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 69:2981–9
- Benet LZ. (2013). The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 102:34–42
- Clive S, Woo MM, Stewart M, et al. (2009). Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat. J Clin Oncol 27:15s
- Evans WE, Relling MV. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–91
- Fallon JK, Neubert H, Goosen TC, Smith PC. (2013a). Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring. Drug Metab Dispos 41:2076–80
- Fallon JK, Neubert H, Hyland R, et al. (2013b). Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res 12:4402–13
- Ghosal A, Hapangama N, Yuan Y, et al. (2004). Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:14–20
- Goey AK, Figg WD. (2016). UGT genotyping in belinostat dosing. Pharmacol Res 105:22–7
- Harbourt DE, Fallon JK, Ito S, et al. (2012). Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem 84:98–105
- Hutzler JM, Tracy TS. (2002). Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355–62
- Jakoby WB, Ziegler DM. (1990). The enzymes of detoxication. J Biol Chem 265:20715–18
- Kang SP, Ramirez J, House L, et al. (2010). A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics 20:638–41
- Lampe JW, Bigler J, Bush AC, Potter JD. (2000). Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev 9:329–33
- Liu H, Sun H, Lu D, et al. (2014a). Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence. Xenobiotica 44:696–707
- Liu W, Liu H, Sun H, et al. (2014b). Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica 44:455–64
- Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40
- Peer CJ, Goey AK, Sissung TM, et al. (2016). UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. J Clin Pharmacol 56:450–60
- Rowland A, Miners JO, Mackenzie PI. (2013). The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121–32
- Sun H, Zhou X, Wu B. (2015). Accurate identification of UDP-glucuronosyltransferase 1A1 (UGT1A1) inhibitors using UGT1A1 overexpressing HeLa cells. Xenobiotica 45:45–53
- Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616
- Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:49–56
- Wang LZ, Ramírez J, Yeo W, et al. (2013). Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One 8:e54522